Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

span> for the third quarter of 2009 and $3.6 million for the fourth quarter of 2008.  For the full year of 2009, total expenses were $40.5 million, compared to $52.8 million for 2008.  Total 2009 R&D expenses were $13.9 million, compared to $23.9 million during 2008.

As of December 31, 2009, Vanda's cash, cash equivalents, and marketable securities totaled approximately $205.3 million.  As of December 31, 2009, a total of approximately 27.6 million shares of Vanda common stock were outstanding.  Net loss per common share for the fourth quarter of 2009 was $0.34, compared to $0.28 for the third quarter of 2009 and $0.28 for the fourth quarter of 2008. For the full year of 2009, net loss per common share was $1.33, compared to $1.92 for the full year of 2008.  

OPERATIONAL HIGHLIGHTS

During the fourth quarter of 2009, Vanda focused its efforts on the successful transition to Novartis of commercial, regulatory and manufacturing documents, materials and supplies relating to Fanapt™.  On January 11, 2010, Vanda announced that Novartis Pharmaceuticals Corporation had launched Fanapt™ in the U.S.  Vanda has explored, and continues to evaluate, the regulatory path and commercial opportunity for Fanapt™ outside of the U.S. and Canada.

Vanda also continued the clinical, regulatory and commercial evaluation of tasimelteon, its selective melatonin receptor agonist, during the fourth quarter of 2009.  Compoun
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Increasing its ... World Films launches its first three episodes of The GMO ... Mile Project this month, as it continues its mission to ... launch, the project's first phase, to “uncover the truth about ... of media. , The GMO Truth Podcast is an expansion ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... toxicology studies for its newly developed Bruton,s tyrosine ... have been completed. The results of these preclinical ... and Drug Administration. The feedback received from the ... ongoing first-in-human study. Additional preclinical work is required ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Quantum Information and Quantum Control at the University of Toronto ... Physics World magazine. , Steinberg led an international ... two-slit interferometer experiment in which a beam of light shone ... screen behind. That famous experiment and the 1927 debates ...
... Coatings, Inc. (OTCQB: ECOC), a leader in the ... developed bio-based GRAS (generally recognized as safe) UV-curable materials ... be used to make coatings that are safe for ... with food and food packaging. Ecology has ...
... AMSTERDAM, December 15, 2011 Amsterdam Molecular Therapeutics ... therapy, announced today that the Company has a negative equity ... of this negative equity position is in line with previous ... is exploring alternatives for additional financing. AMT announced ...
Cached Biology Technology:U of Toronto experiment named top breakthrough of 2011 by Physics World 2Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products 2Amsterdam Molecular Therapeutics Announces Negative Equity Position 2Amsterdam Molecular Therapeutics Announces Negative Equity Position 3
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... new and environmentally friendly process for producing biodiesel fuel ... pounds of poultry industry waste that accumulate annually in ... the July 22 issue of ACS, Journal of ... In the study Mano Misra, Susanta Mohapatra, Narasimharao Kondamudi, ...
... Applying biological molecules from cell membranes to the ... the very basics of cell-to-cell interaction. Two ... biophysicist and colleagues suggest that putting lipids and ... lead to new classes of self-assembling materials for ...
... defective mitochondrial protein called MCLK1 produce elevated amounts of ... according to a study in this week,s JBC these ... longer than normal mice. Mitochondrial oxidative stress is ... reactive oxygen species produced by mitochondria while they make ...
Cached Biology News:New windows opened on cell-to-cell interactions 2New windows opened on cell-to-cell interactions 3
... (CYP450) metabolite postulated to play an autacoid ... In rat cerebral microvessels, 20-HETE is a ... is excreted mainly as the glucuronide conjugate. ... in human urine) is about 10-fold lower ...
... to rapidly and reliably amplify unknown genomic ... APAgene provides hassle-free, ready-to use components, at ... are provided in each kit. The Genome ... filling, localized cloning of genomic DNA, isolating ...
Mol wt: average mol wt16,951.27 Da by calculation...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
Biology Products: